Loading patent…
AssigneesHadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
InventorsYaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Ya'acov, Smadar Cohen, Tsiona Elkayam
Estimating the term…
The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
A method for the treatment of impaired liver function in a subject in need thereof, said impaired liver function resulting from fulminant hepatic failure, hepatectomy and/or a liver disease selected from the group consisting of autoimmune hepatitis, chronic hepatitis C, chronic hepatitis B, primary biliary cirrhosis, primary sclerosing cholangitis, sarcoidosis and biliary atresia, the method comprising administering to said subject a therapeutically effective amount of at least one biocompatible liquid alginate biomaterial, wherein said alginate has a molecular weight in a range of from 1000 to 50000 Da, thereby treating said impaired liver function.
A method for the treatment of impaired liver function in a subject in need thereof, said impaired liver function resulting from fulminant hepatic failure, hepatectomy and/or a liver disease selected from the group consisting of autoimmune hepatitis, chronic hepatitis C, chronic hepatitis B, primary biliary cirrhosis, primary sclerosing cholangitis, sarcoidosis and biliary atresia, the method comprising systemically administering to said subject a therapeutically effective amount of at least one biocompatible alginate biomaterial, thereby treating said impaired liver function, wherein said alginate has a molecular weight in a range of from 1000 to 50000 Da.
A method for treating impaired liver function in a subject in need thereof, the method comprising systemically administering to said subject a therapeutically effective amount of at least one biocompatible alginate biomaterial, wherein said alginate is in a form of a solution of non-cross-linked alginate, and wherein said alginate has a molecular weight in a range of 1000 to 50000 Da thereby treating said impaired liver function.
Dependencies are inferred from the claim text.